Bristol Myers Squibb Company
https://www.bms.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bristol Myers Squibb Company
What's Next For Phase II ADCs
BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.
Regeneron Aiming To Be A Cell And Gene Medicine ‘Powerhouse’
Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline.
Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization
The Japanese pharma said it plans to accelerate development of the antibody-drug conjugate farletuzumab ecteribulin for solid tumors and will develop it independently.
Merck Takes Over Orion-Partnered Prostate Cancer Drug MK-5684
Deal Snapshot: Merck said it would pay potentially more than $1.6bn for an exclusive global license for opevesostat for metastatic castrate-resistant prostate cancer.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abraxis BioScience, Inc.
- AbVitro, Inc.
- Acetylon Pharmaceuticals, Inc.
- Adnexus Therapeutics, Inc.
- Allied-Bristol Life Sciences, LLC
- Amira Pharmaceuticals, Inc.
- Amylin Pharmaceuticals, Inc.
- Avila Therapeutics, Inc.
- Bristol-Myers Company
- Bristol-Myers K.K.
- Bristol-Myers Squibb
- Cardioxyl Pharmaceuticals
- Celgene Corporation
- Cormorant Pharmaceuticals
- Delinia, Inc.
- EngMab AG
- Flexus Biosciences, Inc.
- Gloucester Pharmaceuticals, Inc.
- ißeCa Therapeutics
- IFM Therapeutics
- Impact Biomedicines, Inc.
- Inhibitex, Inc.
- iPierian Inc.
- Juno Therapeutics, Inc.
- Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
- JW Biotechnology (Shanghai) Co., Ltd
- Kosan
- Medarex, Inc.
- Padlock Therapeutics, Inc.
- Pharmion Corporation
- Quanticel Pharmaceuticals, Inc.
- Receptos, Inc.
- RedoxTherapies, Inc.
- Turning Point Therapeutics Inc.
- Westwood-Squibb Pharmaceuticals
- X-BODY, Inc.
- ZymoGenetics, Inc.
- Forbius
- MyoKardia Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice